Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Nanatinostat
- drug: Pembrolizumab
- drug: Valganciclovir
Eligibility
Key Inclusion Criteria:
- Recurrent or metastatic EBV+ nasopharyngeal carcinoma (RM-NPC) for whom no potentially
curative options are available, who have received at least 1 prior line of
platinum-based chemotherapy and no more than 3 prior lines of therapy for RM-NPC.
- Phase 1b exploratory proof-of-concept cohort only: Advanced/metastatic EBV+ non-NPC
solid tumors with no available curative therapies.
- Measurable disease per RECIST v1.1
- ECOG performance status 0 or 1
- Adequate bone marrow and liver function
Key Exclusion Criteria:
- Anti-tumor treatment with cytotoxic drugs, biologic therapy, immunotherapy, or other
investigational drugs within 4 weeks or >5 half-lives, whichever is shorter
- Active CNS disease
- Inability to take oral medication, malabsorption syndrome or any other
gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption
of nanatinostat and valganciclovir
- Active infection requiring systemic therapy
- Active autoimmune disease that has required systemic therapy with modifying agents,
corticosteroids, or immunosuppressive agents
- Positive hepatitis B or hepatitis C
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elizabeth Winters
650-721-6509
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.
